X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

What you should know: Government arbitration is the wrong way to change Medicare

By Juliet Johnson  |    June 10, 2019
As Washington looks to make changes to Medicare, there are right ways and wrong ways to address the challenges patients face. In recent weeks, policymakers have discussed imposing government...   Read More

Fact Check: How the Part B International Pricing Index Model replaces market competition with government-set prices

By Nicole Longo  |    May 3, 2019
One of the most common misconceptions about the administration’s proposed Part B International Pricing Index (IPI) Model is that it would improve competition in Medicare. However, mounting...   Read More

Examining the truth behind clinical trial costs

By John Corea  |    October 2, 2018
Last week, a study appearing in the Journal of the American Medical Association (JAMA) Internal Medicine, evaluated the costs specifically associated with successful clinical trials for novel...   Read More

Five myths about global efforts to combat tuberculosis

By Megan Van Etten  |    September 20, 2018
On September 26, world leaders will convene in New York for the first-ever United Nations (UN) High-Level Meeting on Ending Tuberculosis (TB). This event could not be more critical – or more...   Read More

Fact Check Friday: Getting the facts straight about negotiation in Medicare Part B

By Nicole Longo  |    August 24, 2018
Medicare Part B has been a hot topic in Washington, DC, this summer with an increasing number of conversations about how the program works. Unfortunately, a common misconception keeps popping up...   Read More

Fact Check Friday: The truth about the cost of 340B to patients

By Nicole Longo  |    January 26, 2018
The 340B program was designed to increase access to medicines for vulnerable or uninsured patients through safety-net facilities, but all signs point to 340B doing the opposite – distorting the...   Read More

Fact Check Friday: The truth about IPAB

By Nicole Longo  |    June 9, 2017
This week on Fact Check Friday, we’re taking a closer look at the Independent Payment Advisory Board (IPAB) – the panel tasked with proposing cuts to Medicare if spending exceeds a certain growth...   Read More

3 things to know about 2016 drug approvals

By Andrew Powaleny  |    January 6, 2017
In 2016, the U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) approved 22 new medicines to treat a broad range of illnesses for patients in need. These...   Read More

Fact Check Friday: Biopharmaceutical company communications with payers

By Andrew Powaleny  |    April 29, 2016
Today, we’re examining how and what biopharmaceutical companies communicate with payers about a medicine prior to its approval by the U.S. Food and Drug Administration (FDA). MYTH:...   Read More

Fact Check Friday: The truth about Industry’s role in R&D

By Andrew Powaleny  |    October 23, 2015
As a follow-up to this blog we posted last year, PhRMA is excited to share new data that provides a fresh look at the significant investment of America’s biopharmaceutical companies make in R&D....   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates